Bayer flags strong results of prostate cancer drug

Jun 06, 2011

German chemical and pharmaceutical group Bayer said Monday that its Alpharadin treatment for prostate cancer has shown positive results in advanced trials.

Bayer developed Alpharadin with the Norwegian lab Algeta and tested it on 922 people in Phase III trials, a statement said.

Those on the treatment lived an average 14 months after the course began, compared with an average of 11.2 months for those given a placebo, it added.

The tests were abandoned early to allow the latter to be given Alpharadin as well.

It has not yet been approved for general sale but Bayer has placed strong hopes in the compound, radium-223 chloride, which attacks in bones.

"Around 90 percent of men with advanced prostate cancer have which are the main cause of disability and death in this disease," the statement said.

Prostate cancer is the most frequent form of cancer among men in Northern Europe and the United States. In 2008, an estimated 903,000 men had worldwide and 250,000 died from the disease, Bayer said.

The news was welcomed on Frankfurt's stock exchange, where Bayer shares gained 1.98 percent to 56.53 euros to lead gainers on the DAX index which was 0.27 percent lower overall.

Explore further: Amgen says a study found its cancer drug more effective than rival drug

add to favorites email to friend print save as pdf

Related Stories

Sunshine pill for prostate cancer in 2009

Jan 16, 2007

A tablet designed to emulate the healing power of the sun could be available for the treatment of advanced prostate cancer as early as 2009. But it remains to be seen whether the drug will be the revolution in prostate cancer ...

New treatment hope for prostate cancer

Feb 06, 2009

Scientists at Melbourne's Burnet Institute have developed a potential new treatment for patients with prostate cancer. An article, which described the invention, has recently been published in the prestigious international ...

Recommended for you

How much overdetection is acceptable in cancer screening?

5 hours ago

People have highly variable views on how much overdetection is acceptable in cancer screening, finds a UK survey in The BMJ this week. The authors say invitations for screening "should include clear information on the li ...

Protein may be key to cancer's deadly resurgences

14 hours ago

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.